3 results
This is the first study of MLN3897 in any disease population. It seeks to establish:1) The ability of MLN3897 to modify the signs and symptoms of RA.2)The safety and tolerability of MLN3897 in combination with MTX.3)The PK/PD profile of MLN3897 in…
The current trial aims to demonstrate that sugammadex is generally safe and effective for reversing both moderate and deep block after rocuronium or vecuronium induced NMB in term neonates and young children.
The objectives of this trial are:- To compare experienced pain during GIS using ExEmgel versus Endosgel (continuous measure pain and subjective reported VAS score)- To compare the image quality, including the occurrence of air bubbles during both…